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Background/aim: Factors affecting neurological outcome and the usefulness of neuron-specific enolase (NSE), S-100B, glial fibrillary
acidic protein (GFAP), and procalcitonin (PCT) in predicting neurological outcomes were assessed in patients who survived at least 24
h after cardiopulmonary resuscitation (CPR).
Materials and methods: Thirty successfully resuscitated cardiac arrest patients were included in this prospective clinical study. The
initial cardiac arrest rhythm, duration of CPR, return of spontaneous circulation time, administered doses of adrenaline, base excess,
blood sugar, and hemodynamic parameters were recorded. Patients with Glasgow Outcome Scale (GOS) scores of 1–3 were defined
as Group I and patients with GOS scores of 4–5 were defined as Group II. Serum NSE, GFAP, S-100B, and PCT levels were compared
between the two groups shortly after CPR (hour 0) and at hours 12 and 24 of the postresuscitation period.
Results: Serum S-100B was significantly higher (P = 0.009) in Group II immediately after CPR. Serum S-100B and NSE after CPR at
hours 0, 12, and 24 were significantly lower in patients who survived to hospital discharge. Serum PCT at hours 12 and 24 and serum
S-100B after CPR at 0, 12, and 24 h reached 94.7% sensitivity. Serum NSE, GFAP, S-100B, and PCT specificities were lower than 50%.
Conclusion: In predicting neurological outcomes, serum S-100B has high sensitivity and low specificity immediately after CPR.
Key words: Cardiopulmonary resuscitation, neuron-specific enolase, S-100B, glial fibrillary acidic protein, procalcitonin

1. Introduction
Once spontaneous circulation is ensured, the main factors
determining the survival and life quality in cases in which
the patient underwent cardiopulmonary resuscitation
(CPR) are cerebral hypoxia developing prior to or during
the resuscitation and neurological damage occurring
as a consequence (1). Reperfusion damage is another
important factor affecting neurological recovery after a
successful resuscitation. During reperfusion, inflammatory
mediators are secreted, triggering a sequence of vascular,
cellular, and molecular incidents, which may potentially
cause permanent cerebral damage (2,3). CPR application
is being rapidly developed in light of numerous studies
on the subject and changes are being made to focus on
preventing neurological damage as well as increasing
survival rates (4).
Early determination of neurological prognosis would
help us to detect the patients that would not be harmed by,
* Correspondence: gulayokmd@hotmail.com

and would probably benefit from, neuroprotective methods
at an early stage, contributing to the good management of
the treatment process. Consequently, it would provide a
decrease in morbidity and mortality rates (5,6).
Neurological prognosis is determined using certain
biological markers that can be measured in blood (7–10).
One of the most common markers used for this purpose
is neuron-specific enolase (NSE). This marker is only
found in neurons. The PROPAC study, which investigated
postcardiopulmonary recovery rates, detected low
neurological recovery in cases of high NSE levels (11).
Some studies suggested that patients with high NSE levels
who experienced a decrease during intensive care had a
better prognosis compared to those that did not experience
the same decrease (7,12).
Another marker indicating neurological recovery after
hypoxic cerebral damage is the S-100B protein. S-100B
is found in glia and Schwann cells within the central
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nervous system (8). The level of this protein, which has
a physiological role in neuronal differentiation and
proliferation, increases after cardiopulmonary arrest (8).
The first increase indicates deterioration in the blood–
brain barrier, astroglial damage, and early cerebral edema.
Apart from these two markers, physicians are also guided
by the glial fibrillary acidic protein (GFAP) in long-term
follow-up and prognosis of focal cerebral damage (13).
GFAP is secreted after acute cerebral damage, permeating
the blood–brain barrier to reach the circulation and thus
increasing the GFAP levels. The increase is parallel to the
size of the infarct area within the brain (13,14).
Studies reporting an increase in postcardiac arrest
procalcitonin (PCT) levels stated that the increase marks
a nonspecific inflammatory response rather than a specific
response to infection (14).
We found no publications stating that markers function
together in determination of neurologic prognosis in
patients that underwent postcardiac arrest resuscitation.
This study investigates the factors affecting neurologic
recovery and the effects of NSE, S-100B, GFAP, and PCT
levels in determining neurologic recovery prognoses in
patients that underwent CPR and survived the first 24 h.
2. Materials and methods
2.1. Patients
In this prospective study, we enrolled 42 patients that
underwent CPR between September 2012 and August
2013 at Celal Bayar University Hospital. All cardiac arrest
patients were in the hospital and had unwitnessed arrests.
CPR was performed by anesthesia residents who had
at least 2 years of experience according to the European
Resuscitation Council 2010 guidelines.
Written consents were taken from the relatives of
participants. The following information pertaining
to patients were recorded: initial electrocardiograph
(ECG) rhythms, CPR duration, return of spontaneous
circulation time, post-CPR ECG data, administered doses

of adrenaline, base excess, blood sugar, and hemodynamic
parameters. Participants were transferred to the intensive
care unit at the Celal Bayar University Faculty of Medicine
for routine follow-up and treatment. All patients received
inotropic support to maintain a mean arterial pressure
between 60 and 80 mmHg. The exclusion criteria of the
present study were age under 18 years, head trauma cases,
cases of trauma-related cardiac arrest, cases of status
epilepticus, and patients who died in the first 24 h after
CPR (12 patients). All patients were kept normothermic in
the intensive care unit. Approval for the study was received
from the Ethics Committee of Scientific Research at the
Celal Bayar University Faculty of Medicine (2011-140).
Full patient data from the study are presented in Tables
1–6.
Neurologic conditions of the patients at the time of
blood draws were assessed and recorded in accordance
with the Glasgow Coma Scale. In discharges, all patients
were evaluated using the Glasgow Outcome Scale (GOS)
(15) (Table 1). Patients were divided into two study groups:
Group I contained GOS 1–3 patients (n = 19) and Group II
contained GOS 4–5 patients (n = 11). Serum NSE, GFAP,
S-100B, and PCT levels were compared between groups. In
addition, patients were divided into 2 subgroups according
to the duration of CPR: <10 min (n = 12) and ≥10 min
(n = 18). Serum S-100B, NSE, GFAP, and PCT levels were
compared in subgroups with CPR duration of <10 min
and ≥10 min; the data are given in Table 4. ECG rhythm
was compared to NSE, S-100B, GFAP, and PCT levels at
the beginning of cardiovascular resuscitation and the data
are depicted in Table 6.
2.2. Biochemical assessments
Following resuscitation, blood samples were obtained from
all patients immediately after CPR (0 h), at 12 h, and at 24
h. Blood was centrifuged and serum samples were kept at
–80 °C for batch analysis. Serum GFAP levels were assessed
by enzyme-linked immunosorbent assay with commercial
reagents (Millipore, Temecula, CA, USA) according to

Table 1. Glasgow outcome scale (GOS).
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Score

Functional status

Description

1

Good recovery

Returned to the original functional level and employment with
no deficit

2

Moderate disability

Minor neurological deficit that does not interfere with daily
functioning or work

3

Severe disability

Significant neurological deficit that interferes with daily
activities or prevents return to employment

4

Persistent vegetative state

Coma or severe deficit rendering the patient totally dependent

5

Death

Self-explanatory

OK et al. / Turk J Med Sci
Table 2. Demographic data of patients, initial ECG rhythm, return of spontaneous circulation time,
administered doses of adrenaline, serum glucose levels (0 h, 12 h, 24 h), duration of mechanical
ventilation, and discharge time.
Group I
(n = 19)

Group II
(n = 11)

Age (years)

53.64 ± 8.37

68.63 ± 9.54*

Sex (male/female)

17/2

8/3

Initial ECG rhythm
PEA
Asystole
VT-VF

6 (31.6%)
7 (36.8%)
6 (31.6%)

6 (54.5%)
2 (18.2%)
3 (27.3%)

Return of spontaneous circulation time (min)

17.00 ± 13.73

14.00 ± 18.42

Adrenaline dose (mg)

1.25 ± 0.39

1.52 ± 0.48

Glucose hour 0 (mg/dL)

205.45 ± 133.77

160.22 ± 71.91

Glucose hour 12 (mg/dL)

154.80 ± 51.76

163.10 ± 70.97

Glucose hour 24 (mg/dL)

127.50 ± 23.43

160.0 ± 57.10

Duration of mechanical ventilation (h)

43.9 ± 57.20

187.68 ± 292.70*

Discharge time (h)

327.27 ± 384.79

223.45 ± 142.04

Values are given as means ± SD. ECG: Electrocardiography, PEA: pulseless electrical activity, VT:
ventricular tachycardia, VF: ventricular fibrillation.*P < 0.05. Sex and initial ECG rhythm were
compared using a chi-square test and all other variables were compared with the Mann–Whitney U test.

the manufacturer’s instructions. Serum NSE, S-100B, and
PCT levels were assessed by electrochemiluminescence
with an analyzer (Cobas e411, Roche Diagnostics GmbH,
Mannheim, Germany) and original reagents.
2.3. Statistical analysis
The data were evaluated with SPSS 15.0 (SPSS Inc., Chicago,
IL, USA). Categorical data were described with percentages
and numeric data with mean ± SD (median) (Q1–Q3).
Coherence of the data with normal distribution was tested
with the Kolmogorov–Smirnov test. According to the assay,
normal distribution assumption was not provided; therefore,
comparisons of 2 independent group medians were done
using the Mann–Whitney U test, while for 3 independent
medians we used Kruskal–Wallis variance analysis. The
relationship between two categorical variants was evaluated
with the chi-square test and the Fisher exact test. Bilateral
correlations between numeric variants were tested with
the Spearman correlation coefficient. In demonstration of
a poor GOS score (GOS: 4–5), the predictive value of the
4th general measurement was assessed with ROC analysis,
detecting the area under the curve and the statistical
significance. Sensitivity and specificity values were
calculated for optimum cut-off values.
3. Results
There were 19 patients in Group I and 11 in Group II, as
shown in Table 2. In addition, patients were divided into 2

subgroups according to the duration of CPR (<10 min (n
= 12) and ≥10 min (n = 18)), as shown in Table 4. Patients
were subgrouped according to initial ECG rhythm, with
ventricular fibrillation and ventricular tachycardia (VFVT) (n = 9), pulseless electrical activity (PEA) (n = 12),
and asystole (n = 9), as shown in Table 6. The length of
hospital stays among our patients ranged from 4 to 49
days. Of all the patients, 21 were discharged home and 9
died.
Patients in Group II were significantly older and had
more comorbid diseases compared to Group I (P < 0.05).
No difference was detected in terms of the intensive care
unit stay durations of both groups, while the duration of
mechanical ventilation was longer in Group II than in
Group I (P = 0.011) (Table 2). No statistically significant
difference was detected in comparison of blood sugar
levels measured following resuscitation in Groups I and II
(P < 0.05) (Table 2). No statistically significant difference
was detected in comparison of the administered dose of
adrenaline and base excess between Groups I and II (P
< 0.05). Other findings showed no significant difference
between groups. Moreover, CPR starting time was less
than 5 min in all patients. The duration of CPR ranged
from 3 min to 50 min.
Following CPR, S-100B levels of Group II were
significantly higher than those of Group I (P = 0.009)
(Table 3). Postresuscitation S-100B levels at hour 0 and
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Table 3. Comparison of serum PCT, GFAP, S-100B, and NSE concentrations in the studied patients.

PCT, 0 h (ng/mL)
PCT, 12 h (ng/mL)
PCT, 24 h (ng/ml)
GFAP, 0 h (ng/mL)
GFAP, 12 h (ng/mL)
GFAP, 24 h (ng/mL)
S-100B, 0 h (µg/L)
S-100B, 12 h (µg/L)
S-100B, 24 h (µg/L)
NSE, 0 h (ng/mL)
NSE, 12 h (ng/mL)
NSE, 24 h (ng/mL)

Group I (n = 19)
mean ± SD median (Q1–Q3)

Group II (n = 11)
mean ± SD median (Q1–Q3)

6.09 ± 11.80
0.92 (0.11–5.02)
10.77 ± 12.95
5.72 (0.40–20.50)
9.23 ± 16.68
1.50 (0.08–12.04)
2.74 ± 3.92
1.13 (0.63–3.71)
2.51 ± 4.07
0.69 (0.33–2.53)
1.93 ± 1.99
2.29 (0.27–2.76)
0.45 ± 0.56
0.13 (0.07–0.78)
1.01 ± 1.85
0.16 (0.03–1.43)
0.33 ± 0.59
0.12 (0.05–0.27)
28.08 ± 14.94
17.73 (13.70–42.17)
46.17 ± 74.28
21.74 (17.59–32.11)
44.97 ± 37.56
42.12 (12.44–59.67)

3.92 ± 7.20
0.47 (0.22–4.71)
16.13 ± 30.39
3.60 (0.63–14.76)
15.38 ± 30.38
3.43 (0.63–14.97)
3.56 ± 5.21
1.90 (0.51–2.97)
2.0 ± 1.54
1.55 (0.81–2.85)
2.59 ± 2.64
1.31 (0.42–5.31)
3.05 ± 3.40
1.93 (0.18–6.21)
1.34 ± 2.62
0.28 (0.12–0.59)
0.84 ± 1.51
0.22 (0.14–0.86)
61.96 ± 56.91
34.45 (17.34–110.80)
37.36 ± 36.44
22.48 (17.80–43.51)
31.28 ± 37.24
19.88 (12.88–28.38)

P-value
0.813
0.854
0.245
0.605
0.175
0.518
0.009*
0.582
0.107
0.061
1.0
0.312

PCT: Procalcitonin, GFAP: glial fibrillary acidic protein, NSE: neuron-specific enolase. *P < 0.01, variables were
compared using the Mann–Whitney U test.

PCT levels at hour 12 were significantly higher in patients
with 10 min or longer CPR duration than those for whom
CPR duration was below 10 min (P = 0.031 and P = 0.014)
(Table 4).
When the NSE, S-100B, GFAP, and PCT levels
following CPR at 0, 12, and 24 h were compared in dead
and discharged cases, post-CPR S-100B (P = 0.010)
and NSE (P = 0.021) levels of discharged cases were
significantly lower.
When the NSE, S-100B, GFAP, and PCT values at 0,
12, and 24 h following resuscitation were compared in
all patients, a positive correlation (P = 0.001) was found
between S-100B and NSE at hour 0. Similarly, a positive
correlation (P = 0.009) was detected between S-100B and
PCT values at hour 12.
Groups I and II were compared in subgroups with
CPR durations of <10 min and ≥ 10 min and no statistical
difference was detected between the groups (Table 5).
When the ECG rhythm was compared to NSE, S-100B,
GFAP, and PCT levels at the beginning of cardiovascular
resuscitation, PCT levels in asystolic cases post-CPR were
statistically higher (P = 0.012) (Table 6).
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Sensitivity and specificity values of postresuscitation
PCT, S-100B, GFAP, and NSE at hours 0, 12, and 24 were
calculated for different cut-off values to help determine
the neurological prognosis. A sensitivity level of 94.7%
was detected for PCT at hours 12 and 24 and for S-100B
at 0 (Figure), 12, and 24 h following CPR. NSE sensitivity
was lower than that of the other neurologic markers.
Specificities of all of the markers was calculated to be
below 50% (Table 7).
4. Discussion
In the present study, we investigated NSE, S-100B, GFAP,
and PCT, which are biomarkers that may have an impact on
neurological recovery, and the effect of these biomarkers
on determining the prognosis of neurological recovery in
CPR patients that survived the following 24 h.
Data acquired from the study revealed that patients
with better GOS scores were younger and had fewer
comorbidities than those with a poor GOS score. Shinozaki
et al. observed the aforementioned pattern but found no
statistical significance and reported that men had a higher
prevalence of poor GOS scores compared to women
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Table 4. Comparison of GCS, PCT, GFAP, S-100B, and NSE in patients subdivided according to CPR duration.
Duration of CPR
P-value

≥10 min (n = 18)
mean ± SD median (Q1–Q3)

<10 min (n = 12)
mean ± SD median (Q1–Q3)

GCS, 0 h

5.00 ± 3.67

8.10 ± 6.0

0.293

GCS, 12 h

6.10 ± 4.44

9.00 ± 5.5

0.147

GCS, 24 h

6.80 ± 5.0

9.80 ± 5.69

0.174

PCT, 0 h (ng/mL)

5.46 ± 9.47
0.84 (0.23–5.72)

3.24 ± 8.32
0.48 (0.10–1.38)

0.291

PCT, 12 h (ng/mL)

18.53 ± 30.26*
7.23 (2.20–18.98)

6.21 ± 9.70
0.52 (0.22–15.83)

0.031

PCT, 24 h (ng/mL)

16.54 ± 30.98
3.84 (0.84–13.25)

6.29 ± 9.0
0.44 (0.08–13.49)

0.159

GFAP, 0 h (ng/mL)

3.10 ± 5.20
1.01 (0.54–2.74)

3.47 ± 3.85
2.44 (0.96–4.43)

0.261

GFAP, 12 h (ng/mL)

1.9 ± 1.85
1.16 (0.62–2.77)

2.70 ± 3.96
0.98 (0.57–3.22)

0.792

GFAP, 24 h (ng/mL)

2.6 ± 2.43
2.08 (0.61–3.18)

1.76 ± 2.38
0.61 (0.26–3.04)

0.113

S-100B, 0 h (µg/L)

2.8 ± 3.33*
1.38 (0.34–5.50)

0.60 ± 1.18
0.11 (0.07–0.60)

0.014

S-100B, 12 h (µg/L)

1.41 ± 2.61
0.32 (0.08–0.61)

0.87 ± 1.84
0.15 (0.10–0.75)

0.536

S-100B, 24 h (µg/L)

0.82 ± 1.47
0.27 (0.12–0.80)

0.34 ± 0.62
0.15 (0.09–0.24)

0.159

NSE, 0 h (ng/mL)

60.33 ± 56.17
38.31 (17.29–110.35)

23.56 ± 13.18
18.35 (15.41–33.45)

0.124

NSE, 12 h (ng/mL)

48.70 ± 61.29
23.45 (18.08–46.54)

24.63 ± 17.20
19.18 (16.70–24.20)

0.233

NSE, 24 h (ng/mL)

41.70 ± 42.01
24.63 (14.02–58.29)

25.50 ± 23.81
16.45 (12.10–30.48)

0.291

CPR: Cardiopulmonary resuscitation, GCS: Glasgow Coma Scale, PCT: procalcitonin, GFAP: glial fibrillary acidic
protein, NSE: neuron-specific enolase. *P < 0.05, variables were compared using the Mann–Whitney U test.

(6). Pfeifer et al. (7) and Hayashida et al. (14) found no
difference in terms of age and sex between patients with
good and poor GOS scores. Functional reserve of the
patients and response to resuscitation were reduced by the
existence of comorbidities, such as old age, hypertension
(HT), chronic obstructive pulmonary disease (COPD),
coronary artery disease (CAD), and diabetes mellitus
(DM). Cerebral function is also known to decrease with
aging (16). Therefore, a higher prevalence of relatively
worse neurological scores is understandably found in
older patients among the cases that make up Group II with

a higher rate of comorbidities (HT, COPD, CAD, DM, etc.)
rather than younger patients.
The hypothalamic-hypophyseal axis is greatly affected
by brain ischemia. Adenohypophyseal insufficiency causes
serious metabolic issues and the glucose metabolism
deteriorates in these cases; thus, higher blood sugar levels
can be observed in patients with more severe cerebral
damage (17). Exogenous catecholamines applied in
cardiopulmonary resuscitation can also increase blood
sugar levels (18). In our patients, post-CPR blood sugar
levels were above the acceptable limits. Blood sugar levels
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Table 5. Comparison of CPR duration in Group I and Group II.
Group I (n = 19)

Group II (n = 11)

3.50 ± 0.58
3.5 (3.0–4.0)
25.0 ± 8.66
25.0 (20.0–30.0)

3.80 ± 0.91
3.5 (3.0–5.0)
27.0 ± 21.09
15.0 (10.0–50.0)

P-value

Duration of CPR
<10 min
≥10 min

0.61
0.80

Values are given as mean ± SD, *P < 0.05.

Table 6. Comparison of initial electrocardiographic rhythms and NSE, S-100B, GFAP, and PCT values.
Initial electrocardiographic rhythm
VF-VT (n = 9)
mean ± SD median (Q1–Q3)

PEA (n = 12)
mean ± SD median (Q1–Q3)

Asystole (n = 9)
mean ± SD median (Q1–Q3)

PCT, 0 h (ng/mL)

1.19 ± 1.74
0.40 (0.18–2.05)

1.98 ± 4.95
0.21 (0.04–0.76)

*9.19 ± 12.62
2.70 (0.54–15.34)

PCT, 12 h (ng/mL)

6.25 ± 6.92
4.21 (0.82–10.97)

15.17 ± 34.43
3.60 (0.48–54.17)

12.41 ± 12.91
14.09 (0.53–21.07)

PCT, 24 h (ng/mL)

2.38 ± 2.31
1.50 (0.52–4.30)

15.08 ± 34.46
3.43 (0.29–54.06)

12.64 ± 15.63
9.58 (0.19–18.03)

GFAP, 0 h (ng/mL)

6.79 ± 7.35
1.58 (0.82–12.32)

1.39 ± 1.44
1.13 (0.37–1.99)

2.03 ± 1.86
1.84 (0.49–2.89)

GFAP, 12 h (ng/mL)

2.65 ± 4.0
1.55 (0.67–2.53)

2.44 ± 2.09
2.53 (0.73–4.33)

1.57 ± 1.98
0.88 (0.41–1.94)

GFAP, 24 h (ng/mL)

2.34 ± 2.33
1.70 (0.28–4.03)

3.01 ± 2.98
1.82 (0.42–6.14)

1.96 ± 2.28
1.10 (0.36–2.86)

S-100B, 0 h (µg/L)

1.90 ± 3.54
0.78 (0.11–1.88)

2.95 ± 3.18
2.62 (0.26–6.89)

1.10 ± 1.35
0.41 (0.10–1.90)

S-100B, 12 h (µg/L)

1.21 ± 3.04
0.14 (0.03–0.56)

1.65 ± 2.62
0.45 (0.10–3.00)

0.99 ± 1.75
0.28 (0.12–1.33)

S-100B, 24 h (µg/L)

0.71 ± 1.48
0.12 (0.07–0.64)

1.01 ± 1.82
0.27 (0.21–0.86)

0.38 ± 0.58
0.15 (0.08–0.37)

NSE, 0 h (ng/mL)

49.46 ± 58.33
17.73 (17.12–77.36)

56.60 ± 50.85
30.31 (18.52–114.30)

42.49 ± 46.76
34.83 (17.31–46.38)

NSE, 12 h (ng/mL)

63.29 ± 77.99
23.45 (19.65–89.57)

35.79 ± 45.13
20.97 (18.17–26.95)

26.80 ± 19.65
19.37 (13.29–43.51)

NSE, 24 h (ng/mL)

50.04 ± 41.09
57.51 (12.95–75.86)

38.84 ± 50.28
20.75 (13.15–34.52)

26.18 ± 22.75
18.54 (11.52–38.68)

CPR: Cardiopulmonary resuscitation, PEA: pulseless electrical activity, VT: ventricular tachycardia, VF: ventricular fibrillation,
PCT: procalcitonin, GFAP: glial fibrillary acidic protein, NSE: neuron-specific enolase. *P = 0.012, variables were compared using the
Kruskal–Wallis test.
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Table 7. Sensitivity and specificity rates of PCT, S-100B, GFAP, and NSE at 0, 12, and 24 h for cut-off values.
Area under curve
(95% CI)

P-value

Cut-off value

Sensitivity
(%)

Specificity
(%)

PCT
0h
12 h

0.474
0.521

0.813
0.854

0.182
0.487

84.2
94.7

36.4
30.0

24 h

0.629

0.245

0.386

94.7

45.5

GFAP
0h

0.557

0.606

0.465

84.2

18.2

12 h

0.651

0.175

0.495

84.2

27.3

24 h

0.572

0.519

0.36

84.2

36.4

S-100B
0h

0.789

0.009*

0.0395

94.7

9.1

12 h

0.563

0.582

0.055

94.7

30.0

24 h

0.679

0.107

0.070

94.7

27.3

NSE
0h

0.708

0.061

17.270

78.9

27.3

12 h

0.500

1.000

18.625

63.2

20.0

24 h

0.388

0.312

11.265

84.2

18.2

PCT: Procalcitonin, GFAP: glial fibrillary acidic protein, NSE: neuron-specific enolase. *P < 0.05.

detected during patients’ admissions to intensive care units
can help to predict the course of neurological recovery
(19). Some publications suggested a strong correlation
between high blood sugar levels and poor neurological
prognosis (20,21). However, Pfeifer et al. (7) found no
ROC Curve
1.0

Sensitivity

0.8

0.6

0.4

0.2

0.0

0.0

0.2

0.4
0.6
1 - Specificity

Figure. ROC curve for S-100B at hour 0.

0.8

1.0

significant difference between those with good and poor
GOS scores after evaluating the blood sugar levels of
patients during hospital admission. We, too, detected no
relation between blood sugar levels at 12 and 24 h after
CPR and neurological prognosis.
Besides the evaluation of neurological recovery,
patients were evaluated in regard to discharge. Significant
drops in S-100B and NSE values were detected at 12 and
24 h after resuscitation for discharged patients. Grubb et
al. (22) observed low S-100B and NSE values in surviving
patients at 48 h. Auer et al. (23) similarly found reduced
NSE values in surviving patients. In contrast, some
publications suggested that S-100B has no impact on
mortality (8).
S-100B is a protein secreted from glial cells, having a
half-life of less than 60 min. It is detected in low levels in
healthy people, though serum levels increase following
any neuronal damage; this increase is reported to mark
a poor neurological condition (7,8,22). NSE is found in
neurons, can be detected in serum within 6 h of neuronal
damage, and has a half-life of 24 h. Serum NSE increase
is correlated to the level of cerebral ischemia (24). In this
study, postresuscitation S-100B values were significantly
higher in patients with poor GOS scores and CPR
durations of 10 min or more. In addition, though not
statistically significant, NSE values in patients with poor
GOS scores were much higher than in those with good
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GOS scores. In the literature, S-100B and NSE were used
as prognostic markers in recovery (7–9,23–25). However,
some publications stated no relation between S-100B
and GOS (26). In light of data gathered in this study, we
concluded that increases in concentrations of both glial
and neuronal cells that report damage are valuable in the
determination of post-CPR neurologic prognosis.
PCT is an inflammatory marker that increases after
resuscitation. Once the inflammatory process is triggered,
messenger ribonucleic acid upregulation synthesized by
the calcitonin I gene causes an increase in PCT values in
a 2–3 h period and this increase plateaus within 6–12 h.
It has a half-life of 20–24 h (14). In our study, a positive
correlation was detected between PCT and S-100B levels
at hour 12, though it was more apparent in patients with
poor GOS scores. PCT values were significantly high at
hour 12 in patients with CPR durations of 10 min or more.
Moreover, postresuscitation PCT values of patients with
asystolic ECG rhythms observed at the beginning of CPR
were found to be significantly higher. Twenty-four hour
survival and discharge rates of patients with asystolic ECG
rhythms observed at beginning of CPR are reported to
be much lower compared to those with VF-VT rhythms
(27). In light of these evaluations, the importance of PCT
in determining neurological prognosis can be researched
with much broader studies, and checking serum levels at
certain intervals might be helpful.
In our patients, sensitivity was reported to be 94.7% for
post-CPR PCT and S-100B at hours 0 (Figure), 12, and 24.
NSE sensitivity was lower than that of other neurological
markers. The specificity of all markers was below 50%.
Zingler et al. (28) detected NSE sensitivity and specificity
as follows: day 1, 91% sensitivity, 100% specificity; day 2,
75% and 100%, respectively. Concerning S-100B, Zingler et
al. (28) also observed 64% sensitivity and 100% specificity
on day 1 and then 75% and 100%, respectively, on day 2.
Prohl et al. (29) observed the following sensitivity and
specificity levels: NSE: days 1 and 2, 33% sensitivity, 100%
specificity; S-100B: days 1 and 2, 17% sensitivity and 100%
specificity. Rech et al. (30) observed NSE sensitivity of
35% and specificity of 100% at 24 h. Hachimi-Idrissi et al.
(31) detected S-100B sensitivity of 67% and specificity of
85% at hour 0, and 100% and 88%, respectively, at hour
24. Larsson et al. (32) found GFAP sensitivity of 25% and
specificity of 94% at hour 24 and 30% and 93%, respectively,
at hour 48. Despite the similarity of the sensitivities of the
neurological markers assessed in our study with those of
the literature, our specificity rate was below 50%. Based on

the data, we concluded that postresuscitation neurological
conditions of the patients can be determined following the
PCT, S-100B, and NSE levels, and that S-100B is the most
sensitive postresuscitation marker, which should guide us
to achieve better results.
Researchers started to draw blood samples after
hospital admission in similar studies (7,8,27). This is
within approximately 8 h after cardiac arrest. The blood
samples were collected immediately after cardiac arrest in
this study and this supports the outcome of our study.
Conditions necessitating CPR and the postresuscitation
physiopathological process are multifactorial, affecting
marker specificity and changing the sensitivities. Therefore,
the inability to detect highly selective markers is plausible.
However, the presence of a marker with sensitivity is an
important factor in assessment of prognosis.
The calculated power values for the mean comparisons
of the variables in Tables 3 and 4 were much lower than
expected (e.g., 80%), except for S-100B at 0 h (µg/L) and
NSE at 0 h (ng/mL). This may be thought of as a limitation
of the study. However, even with small group sizes, the
difference between S-100B 0 h means in Groups I and
II was statistically significant. S-100B at 0 h was also a
valuable diagnostic biochemical parameter for the early
detection of neurological prognosis based on validity
analysis. Small sample sizes (in other words, a power
lower than 80%) may cause type 2 errors. Thus, the other
parameters besides S-100B 0 h of Groups I and II may
be recommended for further studies with more patients
(http://www.openepi.com/Power/PowerMean.htm).
Careful assessment of biomarkers represents cellular,
biochemical, or molecular alterations in human tissues,
cells, or fluids, and they are measurable indicators of
normal biological processes, pathogenic processes, or
pharmacological responses to a therapeutic intervention.
Biomarkers, in the hands of intensivists, should provide a
dynamic and powerful approach to diagnose the severity
of the neurological damage and should improve patient
management. In conclusion, our study shows that patients
with low serum S-100B right after CPR had good postCPR GOS scores and that low S-100B and NSE values at
discharge also indicated a good prognosis. Furthermore,
in patients with 10 min or longer CPR durations, high
S-100B at hour 0 and high PCT at hour 12 indicated a
risk for neurological damage. According to our results,
despite its low specificity, the most sensitive biomarker in
determining the postresuscitation neurological prognosis
was serum S-100B concentration.
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